-
Charles River Laboratories International reported fourth-quarter 2025 revenue of US$994.23 million with a net loss of US$276.56 million, alongside full-year 2025 revenue of US$4.02 billion and a net loss of US$144.34 million driven in part by sizeable goodwill and intangible asset impairments.
-
At the same time, the company issued 2026 guidance calling for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80, while appointing veteran healthcare finance executive Glenn G. Coleman as CFO and experienced life sciences lawyer Kerry Dailey as its first Chief Legal Officer to reshape its senior leadership bench.
-
We’ll now examine how the 2026 outlook and the arrival of an experienced new CFO could influence Charles River’s existing investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 34 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
To own Charles River today, you need to believe its role in outsourced preclinical research and advanced modalities will remain essential despite pressure on animal-based testing and recent losses. Near term, the key catalyst is management’s ability to hit its 2026 guidance after sizable impairments, while the biggest risk is that softer demand and cancellations in Discovery and Safety Assessment linger longer than hoped. The new guidance and leadership changes do not fully resolve that risk.
The most relevant update here is the appointment of Glenn Coleman as CFO alongside 2026 guidance for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80. His background running finance and operations at public healthcare companies may matter for how Charles River prioritizes cost savings, manages its balance sheet, and funds investments in areas like NAMs and cell and gene therapy services, all of which tie directly into the company’s main catalysts and margin ambitions.
Yet beneath this improving outlook, investors should be aware that cancellation risk in longer DSA studies and the shift toward non animal testing could still…
Read the full narrative on Charles River Laboratories International (it’s free!)
Charles River Laboratories International’s narrative projects $4.4 billion revenue and $483.2 million earnings by 2028.
Uncover how Charles River Laboratories International’s forecasts yield a $215.73 fair value, a 37% upside to its current price.
Compared with the baseline view, the most pessimistic analysts were assuming revenue would fall about 11.7% per year and still only reach around US$2.8 billion by 2028, while earnings recovered to about US$174 million, so you can see how their concerns about faster adoption of alternative testing and pressure on core animal research services could be sharpened or softened once they fully weigh the latest impairments, leadership changes, and 2026 outlook.
link